North East patients urged to move from ‘blue to new’ inhalers

NHS leaders say the shift improves treatment by addressing not only symptoms but also the underlying cause of asthma – inflammation in the lungs.

The traditional blue inhaler, also known as a reliever inhaler, has been used for more than 50 years to provide fast-acting relief during asthma flare-ups.

Professor Ewan Maule, director of medicines and pharmacy at the North East and North Cumbria Integrated Care Board (Image: Supplied)

Professor Ewan Maule, director of medicines and pharmacy at the North East and North Cumbria Integrated Care Board (ICB), said: “For over 50 years, the blue inhaler has been prescribed for people with asthma, providing quick relief for breathing difficulties.

“We now know that asthma is not just about keeping the airways open, it’s also about controlling the inflammation, or swelling, that causes the symptoms in the first place.”

He said the new inhalers combine symptom relief with anti-inflammatory medication, helping to reduce lung swelling and improve overall management.

Change from ‘blue to new’ (Image: Supplied)

Prof Maule said: “By upgrading to a combined treatment inhaler patients not only get the relief they need but also benefit from treatment that treats the root cause of their asthma.

“This can lead to fewer flare-ups, fewer hospital visits, and better long-term lung health.”

Claire Adams, ICB respiratory clinical lead, said the change could make a real difference to people’s daily lives.

Ms Adams said: “We know that change can feel scary, especially when people have relied on their blue inhaler for years.

“This change in guidance is an opportunity to make a real difference to how asthma is managed.

“The new combination inhalers offer more protection and better control, helping people to live well and breathe more easily.”

Anyone currently using a blue inhaler is being encouraged to speak to their GP about whether a switch to a combination inhaler could benefit them.

GPs generally offer two main types of asthma treatment.

The first, anti-inflammatory reliever (AIR), is for those who have symptoms less than twice a month or only in specific situations such as during pollen season, when near animals, or during physical activity.

The second, a maintenance and reliever therapy (MART) plan, is for patients who experience symptoms more regularly.

Ms Adams said: “Having the right plan and using the right inhaler, in the right way, can make all the difference in managing asthma effectively.

“Reviewing your asthma action plan with a healthcare professional will ensure you understand how to use the right inhaler correctly and get the best protection for your lungs, helping you to live symptom-free.”

Patients looking for more information about moving from “blue to new” inhalers are advised to contact their GP practice.